Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betrixaban PK/PD in Hepatic Impairment
NCT03397888Phase 1Completed
- Sponsor
- Portola Pharmaceuticals
- Start
- Nov 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of betrixaban in venous thromboembolism (VTE) (3 arms), sponsored by Portola Pharmaceuticals. Primary endpoints: Plasma half-life, Time to maximum concentration and 5 more. Started Nov 2017; status: completed.
02
Drugs
betrixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03397888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03397888.